Hepatitis C: State of Medicaid Access Report Card

Washington



Grade	Recommendations to Improve Patient Access		
A+	Continue to ensure broad access to HCV treatment.		

State Overview

As of February 2022, 2,072,103 individuals were enrolled in Medicaid and CHIP.¹ It is estimated that as of 2016, 54,200 people were living with HCV in Washington.² Most beneficiaries, 84 percent, are enrolled in an MCO plan, 15 percent participate in FFS, and 1 percent are in a Primary Care Case Management program.³ Washington Medicaid contracts with the following MCOs: Amerigroup, Community Health Plan of Washington, Coordinated Care of Washington, Molina Healthcare of Washington, and UnitedHealthcare Community Plan.⁴ HCV treatment is excluded from managed care contracts, and covered under the FFS program.⁵

The Washington Medicaid Preferred Drug List includes Mavyret, Sofosbuvir/Velpatasvir, and Epclusa.6

Deductions		Policy		
Prior Authorization		Prior authorization is not required for Mavyret. ⁷		
Fibrosis Restrictions		Washington Medicaid does not impose fibrosis restrictions.8		
Substance Use Restrictions		Washington Medicaid does not impose substance use restrictions. ⁹		
Prescriber Restrictions		Washington Medicaid does not impose prescriber restrictions. 10		
Retreatment Restrictions		Washington Medicaid does not impose retreatment restrictions. ¹¹		
Access in Managed Care		HCV treatment is excluded from managed care contracts, and covered under the FFS program. 12		
Additional Restrictions		Washington Medicaid does not impose additional restrictions. ¹³		
Total Deductions ()		Total Score [100-Deductions]	Grade A+	

Contact Your State Officials

Medicaid Office: ¹⁴ Charissa Fotinos, Medicaid Director, Health Care Authority, State of Washington; Email: charissa.fotinos@hca.wa.gov; Phone: 360-725-9822.

Pharmacy & Therapeutics Committee: 15 Address: N/A; Telephone: (206) 521-2029; Email Address: leta.evaskus@hca.wa.gov.

Key Sources

Preferred Drug List: Apple Health, PDL (May 2022)





Clinical Criteria: Washington State Health Care Authority, Antivirals - Hepatitis C Treatment (Aug. 1, 2019)

- ¹ CMS, Medicaid & CHIP in Washington, https://perma.cc/9BQE-AEG9.
- ² HepVu, Local Data: Washington, https://perma.cc/GQ44-285F.
- ³ Kaiser Family Foundation, Share of Medicaid Population Covered under Different Delivery Systems, https://perma.cc/2P9L-SM4L.
- ⁴ Washington Medicaid, Apple Health Managed Care, https://perma.cc/4XVY-AD5D.
- ⁵ Washington State Health Care Authority & Washington State Department of Health, Hepatitis C Medications: Comprehensive Purchasing Strategies (Oct. 31, 2019) at 10, https://perma.cc/6TVX-2NY8.
- ⁶ Preferred Drug List.
- ⁷ Clinical Criteria.
- ⁸ Clinical Criteria.
- ⁹ Clinical Criteria.
- ¹⁰ Clinical Criteria.
- ¹¹ Clinical Criteria.
- ¹² Washington State Health Care Authority & Washington State Department of Health, Hepatitis C Medications: Comprehensive Purchasing Strategies (Oct. 31, 2019) at 10, https://perma.cc/6TVX-2NY8.
- ¹³ Clinical Criteria.
- ¹⁴ Washington Medicaid, Clinical Collaboration and Initiatives, Contact Us, https://perma.cc/3H9V-YVH5.
- ¹⁵ Washington Medicaid, Washington Prescription Drug Program, Contact Us, https://perma.cc/D9J5-UL6T.

